1. Academic Validation
  2. Opposing roles of ICAT and Wnt/β-catenin signaling in NSC67657-induced monocytic differentiation

Opposing roles of ICAT and Wnt/β-catenin signaling in NSC67657-induced monocytic differentiation

  • Oncotarget. 2017 Jul 22;8(41):69924-69933. doi: 10.18632/oncotarget.19457.
Weijia Wang 1 Yan Zhang 2 Yong Yuan 1 Runqiang Yuan 1 Youye Yang 1 Xiuming Zhang 1 Dongmei Wen 1 Fuda Huang 1 Jinshu Wang 2
Affiliations

Affiliations

  • 1 Department of Laboratory Diagnosis, Sun Yat-Sen University Affiliated Zhongshan Hospital, Sun Yat-Sen University, Zhongshan 528403, PR China.
  • 2 Key Laboratory of Diagnostic Medicine Designated by The Chinese Ministry of Education, Chongqing Medical University, Chongqing 400016, PR China.
Abstract

NSC67657 is a new steroid drug that induces monocytic differentiation of acute myeloid leukemia cells. Here, we demonstrate that NSC67657 has opposing effects on expression of downstream targets of inhibitor of β-catenin and TCF (ICAT) and Wnt signaling in HL60 cells. ICAT binds to β-catenin, and this interaction is further increased in NSC67657-differentiated cells. ICAT overexpression decreases expression of Wnt downstream targets and increases sensitivity of HL60 cells to NSC67657, while ICAT silencing increases Wnt signaling and delays the NSC67657-induced cell differentiation. In addition, pharmacological inhibition of Wnt/β-catenin signaling increases the NSC67657-induced cell differentiation, while activation of Wnt/β-catenin signaling inhibits the differentiation, indicating Wnt/β-catenin signaling inhibits NSC67657-induced monocytic differentiation of HL60 cells. Our data demonstrate the opposing roles of ICAT and Wnt signaling in the NSC67657-induced monocytic differentiation, and suggest that ICAT and Wnt signaling may serve as therapeutic targets for leukemia chemotherapy.

Keywords

HL60 cells; ICAT; NSC67657; Wnt/β-catenin signaling pathway; monocytic differentiation.

Figures
Products